1 p.m. - 2 p.m.
Registration here.
This hybrid session is open to doctors and healthcare professionals only. 1 CME point will be awarded.
Surgery remains the cornerstone in the curative treatment of most adult solid tumors. The use of drug treatment and/or radiotherapy before surgery offers many advantages such as tumor reduction and early treatment of micrometastases. The advent of modern drugs such better chemotherapy and immunotherapy is reshaping the ways we treat common cancers such as breast, lung and rectal cancers. The ultimate goal is to improve cure rates.
Our Speaker
Dr. Kong Hwai Loong
Medical Oncologist
Dr. Kong Hwai Loong received his medical degree from National University of Singapore [NUS] in 1988, where he graduated top of his medical class. He subsequently qualified in the Internal Medicine specialty in 1993 by earning his Master of Medicine (Internal Medicine) from NUS, as well as his Membership to the Royal College of Physician (UK). For his research accomplishments in anti-angiogenesis and gene therapy, Dr. Kong was conferred the Singapore Young Scientist Award. He was also the first Singaporean to be awarded the American Society of Clinical Oncology (ASCO) Merit Award. He was a two-time winner of the prestigious Singapore Youth Award, the highest accolade awarded to Youths in Singapore. For his contribution to scientific research and research administration in Singapore, Dr. Kong received the National Day Award from the President of Singapore.
Dr. Kong specializes in the diagnosis and treatment of adult cancers. He is passionate about medical education, and has lectured widely on oncology-related and youth-related topics.
Dr. Kong's specialty interests are breast, urogenital, gastrointestinal and lung cancers, and melonomas.
